| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.09 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.09 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.21 | 0.1 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.087 | 0.1 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.1 |